Stock Movers

Johnson & Johnson’s Second-Quarter Sales Slow But Outcome Tops Expectations

Johnson & Johnson’s Second-Quarter Sales Slow But Outcome Tops Expectations

Johnson & Johnson (JNJ), the maker of consumer, pharmaceutical and medical, reported declines in sales for its second quarter although the result was still better than the consensus, while earnings also came in ahead of expectations. Reported sales fell 1.3% to $20.56 billion, but that was ahead of the consensus […]

LiveRamp Releases Full-Year Guidance as Fourth Quarter Results Beat Street Views

LiveRamp unveiled full-year guidance after markets closed on Tuesday as it posted better-than-expected results for its fiscal fourth quarter, which were supported by double-digit growth in subscriptions revenue. The San Francisco-headquartered identity platform generated total revenue of $78.3 million in the three months ended March 31, up 30.1% from the […]

Regis Signs Sale, Conversion Agreement for 190 Ohio Salons

Regis (RGS) on Wednesday said it has agreed to sell and convert a further 190 company-owned salons to its asset-light franchise portfolio located in Ohio and surrounding areas to Super C Group. No financial terms were disclosed. The salons will be remodeled and converted to Supercuts and Cost Cutters over […]

Capri Shares Slump 10% Pre-Bell on Downbeat Outlook

Capri Holdings (CPRI ), whose luxury fashion brands include Jimmy Choo and Michael Kors, said Wednesday fiscal Q4 adjusted earnings were $0.63 per share, unchanged from the prior-year period and higher than the $0.61 earnings-per-share estimate provided by Capital IQ. Revenue for the quarter ended March 30 was $1.34 billion, […]

Canada Goose Q4 Tops Street on EPS, Misses on Revenue

Canada Goose (GOOS, GOOS.TO) is down more than 14% in pre-market trading as the luxury apparel retailer posted fiscal Q4 adjusted earnings of CAD0.09 ($0.07) per share, flat with CAD0.09 in the same period a year ago and exceeding the estimate of CAD0.05 from analysts polled by Capital IQ. For […]

Cara Therapeutics Posts Positive Trial Data For Korsuva Injection To Treat Pruritus

Cara Therapeutics (CARA) on Wednesday reported positive topline data from the KALM-1 phase 3 trial of Korsuva Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Shares surged 18% to $21.22 in pre-market trade. The company is “encouraged by the early anti-pruritic response with Korsuva Injection, which resulted […]